CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q1 2023
Institutional positions in CRISPR Therapeutics AG as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 383
- −9 vs. Q4 2022
- Shares held
- 56.2M
- +749.3K (+1.4%) vs. Q4 2022
- Total value
- $2.54B
- +$287.4M (+12.7%) vs. Q4 2022
- New holders
- 49
- 103 more added
- Sold out
- 58
- 120 more reduced
7 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 525 | $4.16B |
| Q1 2026 | 494 | $3.67B |
| Q4 2025 | 482 | $4.01B |
| Q3 2025 | 442 | $4.68B |
| Q2 2025 | 435 | $3.52B |
| Q1 2025 | 398 | $2.20B |
| Q4 2024 | 406 | $2.54B |
| Q3 2024 | 417 | $2.81B |
| Q2 2024 | 450 | $3.22B |
| Q1 2024 | 483 | $4.10B |
| Q4 2023 | 472 | $3.48B |
| Q3 2023 | 410 | $2.50B |
| Q2 2023 | 420 | $3.07B |
| Q1 2023 | 383 | $2.54B |
| Q4 2022 | 399 | $2.26B |
| Q3 2022 | 436 | $3.70B |
| Q2 2022 | 437 | $3.35B |
| Q1 2022 | 446 | $3.10B |
| Q4 2021 | 448 | $3.25B |
| Q3 2021 | 477 | $4.53B |
| Q2 2021 | 501 | $6.57B |
| Q1 2021 | 446 | $5.20B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding CRISPR Therapeutics AG; share changes are against Q4 2022.